JPMorgan lowered the firm’s price target on Novo Nordisk (NVO) to DKK 1,000 from DKK 1,050 and keeps an Overweight rating on the ...

In a report released today, Elmar Kraus from DZ BANK AG maintained a Hold rating on Novo Nordisk (0QIU – Research Report). The company’s shares ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a clinical trial. Shares were 10 ...

--Currently up two consecutive days; up 9.05% over this period --Best two day stretch since the two days ending Aug. 9, 2024, when it rose 11.94% --Up 2.14% month-to-date; on pace for best month ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

Jan 16 (Reuters) - Novo Holdings, the controlling shareholder of Novo Nordisk (NOVOb.CO), opens new tab, hopes to double the size of its recently acquired contract drugmaker Catalent over five ...

I’m cautious about Novo Nordisk's stock in the short term due to the recent selloff momentum, which could bottom out if the FDA rejects its petition to restrict compounding alternatives.